MX2010010968A - Compuestos y composiciones como inhibidores de cinasa de proteina. - Google Patents
Compuestos y composiciones como inhibidores de cinasa de proteina.Info
- Publication number
- MX2010010968A MX2010010968A MX2010010968A MX2010010968A MX2010010968A MX 2010010968 A MX2010010968 A MX 2010010968A MX 2010010968 A MX2010010968 A MX 2010010968A MX 2010010968 A MX2010010968 A MX 2010010968A MX 2010010968 A MX2010010968 A MX 2010010968A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- compositions
- protein kinase
- kinase inhibitors
- pyrimidine derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Abstract
La invención proporciona novedosos derivados de pirimidina y composiciones farmacéuticas de los mismos, y métodos para utilizar estos compuestos. Por ejemplo, los derivados de pirimidina de la invención se pueden utilizar para tratar, mitigar, o prevenir una condición que responda a la inhibición de la actividad de cinasa de linfoma anaplásico (ALK), del oncogén c-ros (ROS), del factor de crecimiento tipo insulina (IGF-1R), y/o del receptor de insulina (lnsR), o de una combinación de los mismos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4311108P | 2008-04-07 | 2008-04-07 | |
US11602308P | 2008-11-19 | 2008-11-19 | |
PCT/US2009/039383 WO2009126515A1 (en) | 2008-04-07 | 2009-04-03 | Compounds and compositions as protein kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2010010968A true MX2010010968A (es) | 2010-10-26 |
Family
ID=40756678
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2010010968A MX2010010968A (es) | 2008-04-07 | 2009-04-03 | Compuestos y composiciones como inhibidores de cinasa de proteina. |
Country Status (12)
Country | Link |
---|---|
US (1) | US8592432B2 (es) |
EP (1) | EP2271630B1 (es) |
JP (1) | JP5298187B2 (es) |
KR (1) | KR101238585B1 (es) |
CN (1) | CN102131788B (es) |
AU (1) | AU2009233964B2 (es) |
BR (1) | BRPI0911228A2 (es) |
CA (1) | CA2720946C (es) |
EA (1) | EA018282B1 (es) |
ES (1) | ES2570127T3 (es) |
MX (1) | MX2010010968A (es) |
WO (1) | WO2009126515A1 (es) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI389893B (zh) | 2007-07-06 | 2013-03-21 | Astellas Pharma Inc | 二(芳胺基)芳基化合物 |
US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
CA2723961C (en) | 2008-05-21 | 2017-03-21 | Ariad Pharmaceuticals, Inc. | Phosphorous derivatives as kinase inhibitors |
AU2010211672B2 (en) * | 2009-02-06 | 2016-08-04 | Nippon Shinyaku Co., Ltd. | Aminopyrazine derivative and medicine |
PL2428508T3 (pl) | 2009-05-08 | 2016-05-31 | Astellas Pharma Inc | Diaminoheterocykliczny związek karboksyamidowy |
BR112012033253A2 (pt) | 2010-06-23 | 2016-11-22 | Hanmi Science Co Ltd | novos derivados de pirimidina fundidos para inibição da atividade de tirosina quinase |
WO2012005299A1 (ja) * | 2010-07-07 | 2012-01-12 | 日本新薬株式会社 | Rosチロシンキナーゼ阻害剤 |
RU2013120966A (ru) * | 2010-10-08 | 2014-11-20 | Эббви Инк. | ФУРО[3,2-d]ПИРИМИДИНОВЫЕ СОЕДИНЕНИЯ |
CA2810900A1 (en) * | 2010-10-14 | 2012-04-19 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in egfr-driven cancers |
EP3453708B8 (en) * | 2010-12-17 | 2022-03-16 | Novartis AG | Process for the preparation of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2, 4-diamine di-hydrochloride |
US8362023B2 (en) | 2011-01-19 | 2013-01-29 | Hoffmann-La Roche Inc. | Pyrazolo pyrimidines |
CN103458881B (zh) * | 2011-02-02 | 2015-08-12 | Irm责任有限公司 | Alk抑制剂的使用方法 |
CN102757390B (zh) * | 2011-04-27 | 2015-04-22 | 中国中化股份有限公司 | 一种制备2-甲氧基-4-肼基-5-氟嘧啶的方法 |
CN103501612B (zh) | 2011-05-04 | 2017-03-29 | 阿里亚德医药股份有限公司 | 抑制表皮生长因子受体导致的癌症中细胞增殖的化合物 |
KR101379808B1 (ko) | 2012-04-03 | 2014-04-24 | 울산대학교 산학협력단 | 산화질소 생성 억제용 피라졸로피리미딘 유도체 화합물 |
WO2013169401A1 (en) | 2012-05-05 | 2013-11-14 | Ariad Pharmaceuticals, Inc. | Compounds for inhibiting cell proliferation in egfr-driven cancers |
CN104854101B (zh) | 2012-11-06 | 2018-05-01 | 上海复尚慧创医药研究有限公司 | Alk激酶抑制剂 |
CN102977104A (zh) * | 2012-11-26 | 2013-03-20 | 盛世泰科生物医药技术(苏州)有限公司 | 2,4-二氯-7-氢-吡咯并(2,3)嘧啶的合成 |
US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
CN104109149B (zh) * | 2013-04-22 | 2018-09-28 | 苏州泽璟生物制药有限公司 | 氘代的二氨基嘧啶化合物以及包含该化合物的药物组合物 |
CN104672214B (zh) * | 2013-12-03 | 2019-04-12 | 上海翰森生物医药科技有限公司 | 具有alk抑制活性的化合物及其制备与用途 |
CN105848682A (zh) * | 2013-12-23 | 2016-08-10 | 诺华股份有限公司 | 药物组合 |
CA2940918C (en) | 2014-03-27 | 2023-10-24 | Janssen Pharmaceutica Nv | Substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-.alpha.]pyrazine derivatives and 5,6,7,8-tetrahydro-4h-pyrazolo[1,5-.alpha.][1,4]diazepine derivatives as ros1 inhibitors |
US10053458B2 (en) | 2014-06-17 | 2018-08-21 | Korea Research Institute Of Chemical Technology | Pyrimidine-2,4-diamine derivative and anticancer pharmaceutical composition comprising same as effective ingredient |
CN105524045B (zh) * | 2014-10-22 | 2020-04-10 | 山东轩竹医药科技有限公司 | 四环类间变性淋巴瘤激酶抑制剂 |
CN104803908A (zh) * | 2015-03-26 | 2015-07-29 | 药源药物化学(上海)有限公司 | 2-异丙氧基-5-甲基-4-(4-哌啶基)苯胺二盐酸盐的水合物、其制备方法及用途 |
CN106188060A (zh) * | 2015-04-29 | 2016-12-07 | 厦门大学 | 嘧啶并吡咯类化合物、其制备方法、药用组合物及其应用 |
CN106699810A (zh) * | 2015-11-17 | 2017-05-24 | 清华大学 | 一种含氮杂环化合物及其制备方法与在抑制激酶活性中的应用 |
CN107216319B (zh) * | 2016-03-21 | 2021-10-08 | 中国科学院上海药物研究所 | 一种2,4-二氨基嘧啶类衍生物、其制备方法及用途 |
KR101937529B1 (ko) * | 2016-07-26 | 2019-01-14 | 한국화학연구원 | 신규한 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 |
SG10201914030UA (en) | 2016-08-29 | 2020-03-30 | Univ Michigan Regents | Aminopyrimidines as alk inhibitors |
CN107793417B (zh) * | 2016-09-05 | 2020-06-09 | 复旦大学 | 吡咯并[2,3-d]嘧啶类化合物及其盐,及制备方法和药用用途 |
CN110114357B (zh) * | 2016-10-28 | 2022-05-31 | 百时美施贵宝公司 | 可用作IL-12、IL-23和/或IFNα反应的调节剂的杂双环化合物 |
CN108276410B (zh) * | 2017-01-06 | 2021-12-10 | 首药控股(北京)股份有限公司 | 一种间变性淋巴瘤激酶抑制剂及其制备方法和用途 |
KR102032418B1 (ko) * | 2017-06-15 | 2019-10-16 | 한국화학연구원 | 접합 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 브루톤티로신 키나제 활성 관련 질환의 예방 또는 치료용 약학적 조성물 |
US20190338244A1 (en) * | 2017-11-30 | 2019-11-07 | New York Medical College | Multipotent adult stem cells: characterization and use |
CN112645929B (zh) * | 2019-10-11 | 2022-03-11 | 苏州泽璟生物制药股份有限公司 | 异丙磺酰基苯基嘧啶类化合物或其盐的多晶型物 |
WO2021073498A1 (zh) * | 2019-10-17 | 2021-04-22 | 贝达药业股份有限公司 | Egfr抑制剂、组合物及其制备方法 |
CN111484484B (zh) * | 2020-04-13 | 2021-11-23 | 沈阳药科大学 | 含芳杂环的2,4-二芳氨基嘧啶衍生物及其制备与应用 |
WO2023128708A1 (ko) * | 2021-12-30 | 2023-07-06 | 한국화학연구원 | 피라졸로피리미딘 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물 |
CN114805301B (zh) * | 2022-04-29 | 2024-04-05 | 沈阳药科大学 | 2,4-二芳氨基嘧啶类化合物及其制备方法和应用 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT874846E (pt) * | 1995-11-01 | 2003-08-29 | Novartis Ag | Derivados de purina e processos para a sua preparacao |
UA80767C2 (en) * | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
GB0305929D0 (en) * | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
CN102358738A (zh) | 2003-07-30 | 2012-02-22 | 里格尔药品股份有限公司 | 2,4-嘧啶二胺化合物及其预防和治疗自体免疫疾病的用途 |
DE602004032446D1 (de) * | 2003-08-07 | 2011-06-09 | Rigel Pharmaceuticals Inc | 2,4-pyrimidindiamin-verbindungen und verwendungen als antiproliferative mittel |
PL1660458T3 (pl) | 2003-08-15 | 2012-07-31 | Novartis Ag | 2,4-pirymidynodwuaminy stosowane w leczeniu chorób nowotworowych, chorób zapalnych i zaburzeń układu immunologicznego |
WO2005111016A1 (en) * | 2004-05-14 | 2005-11-24 | Pfizer Products Inc. | Pyrimidine derivatives for the treatment of abnormal cell growth |
EP1598343A1 (de) * | 2004-05-19 | 2005-11-23 | Boehringer Ingelheim International GmbH | 2-Arylaminopyrimidine als PLK Inhibitoren |
GB0419161D0 (en) * | 2004-08-27 | 2004-09-29 | Novartis Ag | Organic compounds |
AU2005309019A1 (en) * | 2004-11-24 | 2006-06-01 | Novartis Ag | Combinations of JAK inhibitors and at least one of Bcr-Abl, Flt-3, FAK or RAF kinase inhibitors |
JP2008013527A (ja) * | 2006-07-10 | 2008-01-24 | Sankyo Co Ltd | チエノ[3,2−d]ピリミジン−2,4−ジアミン誘導体 |
WO2008039359A2 (en) * | 2006-09-25 | 2008-04-03 | Janssen Pharmaceutica N.V. | Bicyclic pyrimidine kinase inhibitors |
TWI432427B (zh) | 2006-10-23 | 2014-04-01 | Cephalon Inc | 作為ALK及c-MET抑制劑之2,4-二胺基嘧啶之融合雙環衍生物 |
EP3012249A1 (en) * | 2006-12-08 | 2016-04-27 | Novartis AG | Compounds and composition as protein kinase inhibitors |
AU2007333394C1 (en) * | 2006-12-08 | 2011-08-18 | Novartis Ag | Compounds and compositions as protein kinase inhibitors |
WO2009032694A1 (en) * | 2007-08-28 | 2009-03-12 | Dana Farber Cancer Institute | Amino substituted pyrimidine, pyrollopyridine and pyrazolopyrimidine derivatives useful as kinase inhibitors and in treating proliferative disorders and diseases associated with angiogenesis |
WO2009032668A2 (en) * | 2007-08-28 | 2009-03-12 | Irm Llc | 2 -biphenylamino-4 -aminopyrimidine derivatives as kinase inhibitors |
-
2009
- 2009-04-03 MX MX2010010968A patent/MX2010010968A/es active IP Right Grant
- 2009-04-03 CN CN200980121030.5A patent/CN102131788B/zh not_active Expired - Fee Related
- 2009-04-03 US US12/936,199 patent/US8592432B2/en not_active Expired - Fee Related
- 2009-04-03 ES ES09730392T patent/ES2570127T3/es active Active
- 2009-04-03 KR KR1020107024933A patent/KR101238585B1/ko not_active IP Right Cessation
- 2009-04-03 EA EA201001597A patent/EA018282B1/ru not_active IP Right Cessation
- 2009-04-03 AU AU2009233964A patent/AU2009233964B2/en not_active Ceased
- 2009-04-03 JP JP2011504086A patent/JP5298187B2/ja not_active Expired - Fee Related
- 2009-04-03 BR BRPI0911228A patent/BRPI0911228A2/pt not_active IP Right Cessation
- 2009-04-03 WO PCT/US2009/039383 patent/WO2009126515A1/en active Application Filing
- 2009-04-03 EP EP09730392.9A patent/EP2271630B1/en not_active Not-in-force
- 2009-04-03 CA CA2720946A patent/CA2720946C/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US8592432B2 (en) | 2013-11-26 |
BRPI0911228A2 (pt) | 2017-05-30 |
CN102131788A (zh) | 2011-07-20 |
EP2271630A1 (en) | 2011-01-12 |
CA2720946A1 (en) | 2009-10-15 |
KR20110015414A (ko) | 2011-02-15 |
EA018282B1 (ru) | 2013-06-28 |
WO2009126515A8 (en) | 2010-10-21 |
US20110135668A1 (en) | 2011-06-09 |
CN102131788B (zh) | 2014-03-19 |
JP5298187B2 (ja) | 2013-09-25 |
EP2271630B1 (en) | 2016-03-23 |
ES2570127T3 (es) | 2016-05-17 |
WO2009126515A1 (en) | 2009-10-15 |
AU2009233964B2 (en) | 2012-06-07 |
CA2720946C (en) | 2013-05-28 |
KR101238585B1 (ko) | 2013-02-28 |
AU2009233964A1 (en) | 2009-10-15 |
EA201001597A1 (ru) | 2011-06-30 |
JP2011516555A (ja) | 2011-05-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2010010968A (es) | Compuestos y composiciones como inhibidores de cinasa de proteina. | |
MX2010002336A (es) | Derivados de 2-bifenil-amino-4-amino-pirimidina como inhibidores de cinasa. | |
JO3403B1 (ar) | مركبات وتركيبات في صورة مثيطات إنزيم كيناز بروتين | |
WO2009126514A8 (en) | Compounds and compositions as kinase inhibitors | |
MX2009006081A (es) | Compuestos y composiciones como inhibidores de cinasa de proteina. | |
WO2010002655A3 (en) | Pyrimidine derivatives as kinase inhibitors | |
UA101057C2 (en) | Pyrimidine derivatives as kinase inhibitors | |
WO2010005876A3 (en) | Polycyclic heteroaryl substituted triazoles useful as axl inhibitors | |
WO2012017239A3 (en) | 4-(1h-indol-3-yl) -pyrimidines as alk inhibitors | |
WO2009114870A3 (en) | Kinase inhibitors and methods of use | |
AU2011276193A8 (en) | Bipyridyl derivatives useful for the treatment of kinase - induced diseases | |
WO2008083367A3 (en) | Polycyclic heteroaryl substituted triazoles useful as axl inhibitors | |
MX2009011950A (es) | Derivados de pirimidina y composiciones como inhibidores de cinasa c-kit y pdgfr. | |
HK1181753A1 (en) | Pyrimidine compounds as inhibitors of protein kinases ikk epsilon and/or tbk-1, processes for their preparation, and pharmaceutical compositions containing them ikk/ tbk-1 | |
MX2009009117A (es) | Derivados de pirimidin-2,4-diamina y su uso como inhibidores de la cinasa jak2. | |
WO2010104598A3 (en) | Kinase protein binding inhibitors | |
WO2009094560A3 (en) | Thienopyranones as kinase inhibitors | |
MX2009012079A (es) | Compuestos heterociclicos condensados como inhibidores de proteina cinasas. | |
TN2010000602A1 (en) | Pyrimidine derivatives as kinase inhibitors | |
WO2009105238A3 (en) | Kinase protein binding inhibitors | |
UA106975C2 (uk) | Похідні піримідину й способи інгібування сигнального шляху jak | |
UA105483C2 (uk) | Похідні ізохінолінону, композиція на їх основі та застосування як інгібіторів рі3k |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |